Fibrinogen-Albumin-Ratio is an independent predictor of thromboembolic complications in patients undergoing VA-ECMO.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
17 08 2021
17 08 2021
Historique:
received:
10
06
2021
accepted:
22
07
2021
entrez:
18
8
2021
pubmed:
19
8
2021
medline:
18
11
2021
Statut:
epublish
Résumé
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) supports patients suffering from refractory cardiogenic shock. Thromboembolic complications (TeC) are common in VA-ECMO patients and are associated with increased morbidity and mortality. Valid markers to predict TeC in VA-ECMO patients are lacking. The present study investigated the predictive value of baseline Fibrinogen-Albumin-Ratio (FAR) for in-hospital TeC in patients undergoing VA-ECMO. This retrospective cohort study included patients who underwent VA-ECMO therapy due to cardiogenic shock at the University Hospital Duesseldorf, Germany between 2011 and 2018. Main exposure was baseline FAR measured at initiation of VA-ECMO therapy. The primary endpoint was the in-hospital incidence of TeC. In total, 344 patients were included into analysis (74.7% male, mean age 59 ± 14 years). The in-hospital incidence of TeC was 34%. Receiver operating characteristics (ROC) curve of FAR for in-hospital TeC revealed an area under the curve of 0.67 [95% confidence interval (CI) 0.61-0.74]. Youden index determined a cutoff of 130 for baseline FAR. Multivariate logistic regression revealed an adjusted odds-ratio of 3.72 [95% CI 2.26-6.14] for the association between FAR and TeC. Baseline FAR is independently associated with in-hospital TeC in patients undergoing VA-ECMO. Thus, FAR might contribute to the prediction of TeC in this cohort.
Identifiants
pubmed: 34404824
doi: 10.1038/s41598-021-95689-x
pii: 10.1038/s41598-021-95689-x
pmc: PMC8371004
doi:
Substances chimiques
Albumins
0
Biomarkers
0
Fibrinogen
9001-32-5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16648Informations de copyright
© 2021. The Author(s).
Références
ASAIO J. 2020 Mar;66(3):277-282
pubmed: 30973402
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Lancet. 2018 Jun 9;391(10137):2325-2334
pubmed: 29900874
Ann Intensive Care. 2016 Dec;6(1):66
pubmed: 27432243
Platelets. 2020 Jul 3;31(5):674-679
pubmed: 32367765
Anesth Analg. 2020 Jul;131(1):187-195
pubmed: 32102011
Stroke. 2021 Jul;52(7):e364-e467
pubmed: 34024117
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620933008
pubmed: 32598182
Med Klin Intensivmed Notfmed. 2021 Feb;116(1):56-58
pubmed: 33146748
BMC Cancer. 2020 Jul 25;20(1):691
pubmed: 32711484
Artif Organs. 2016 Aug;40(8):E136-45
pubmed: 27530673
JACC Heart Fail. 2016 Sep;4(9):698-708
pubmed: 27179833
J Biomed Mater Res. 1990 Feb;24(2):155-63
pubmed: 2329112
Anesthesiology. 2019 Jul;131(1):84-93
pubmed: 31094760
Crit Care. 2021 Apr 29;25(1):160
pubmed: 33910609
Eur Heart J. 2015 Sep 1;36(33):2246-56
pubmed: 26033984
Ann Thorac Surg. 2017 Jul;104(1):130-137
pubmed: 28189274
Int J Biochem Cell Biol. 1999 Jul;31(7):741-6
pubmed: 10467729
J Thorac Cardiovasc Surg. 2018 Nov;156(5):1894-1902.e3
pubmed: 30343699
J Am Coll Cardiol. 2014 Oct 7;64(14):1407-15
pubmed: 25277608
Crit Care Med. 2020 Dec;48(12):1920-1921
pubmed: 33255117
Circ Heart Fail. 2018 Sep;11(9):e004905
pubmed: 30354364
J Clin Med. 2020 Jun 03;9(6):
pubmed: 32503278
J Cardiothorac Vasc Anesth. 2013 Feb;27(1):30-4
pubmed: 23036625
J Intensive Care Med. 2020 Jul;35(7):679-686
pubmed: 29768983
Crit Care Med. 2021 Jul 1;49(7):1107-1117
pubmed: 33729722
Thorac Cardiovasc Surg. 2021 Apr;69(3):263-270
pubmed: 32035427